Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT942524PRCRPACCCTA: DoD Peer Reviewed Cancer, Advancing Cancer Care Through Clinical Trials Award

Closed Closed October 15, 2024 Opportunity HT942524PRCRPACCCTA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2024.

• Total funding$24.0 million
• Expected awards5
• Cost sharingNot required
• Funding typeGrant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY24 PRCRP ACCCTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY24 PRCRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of- concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial. Key aspects of the PRCRP Award Mechanism: · Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for studies regulated by the Regulatory Agency. · Impact: The proposed intervention(s) to be tested should offer significant potential for advancing to the next stage of clinical study, transition of results to fielded science, or improve the standard of care for at least one of the FY24 PRCRP Topic Areas and address one of the FY24 PRCRP Military Health Focus Areas and one of the FY24 PRCRP Overarching Challenges. The impact of the intervention should include considerations of quality of life and supportive care during the trial. · Supportive preclinical data are required: Inclusion of supportive preclinical data relevant for the clinical trial is required. No proposed preclinical research to support an IND/ IDE application is allowed. The data presented to support the initiation of a clinical trial is required. No animal work is allowed. · Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.